Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Convergence is going virtual. Join the brightest minds in regulatory online to gain the latest knowledge in the field in an all-virtual experience with workshops, one-on-one expert sessions, and networking communities.
This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
The last exam window of 2020 is currently open. Register by 8 October to take the RAC exam this autumn.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 22 December 2016 | By Zachary Brennan
The US Food and Drug Administration (FDA) on Thursday announced the latest batch of new draft guidance for the generic drug industry with 31 product-specific bioequivalence (BE) recommendations and 13 revisions to prior recommendations.
The recommendations, which have been released on an ongoing basis since 2010, provide product-specific guidance on the design of BE studies to support abbreviated new drug applications (ANDAs).
The new guidance is for the following active ingredients: 1. Adapalene; benzoyl peroxide 2. Amphetamine 3. Betamethasone valerate 4. Budesonide 5. Cephalexin 6. Cetirizine hydrochloride 7. Clozapine 8. Colchicine 9. Doxycycline hyclate 10. Emtricitabine; Rilpivirine hydrochloride; Tenofovir alafenamide fumarate 11. Emtricitabine; Tenofovir alafenamide fumarate 12. Epinephrine 13. Esomeprazole Magnesium 14. Ethiodized oil 15. Fenofibrate 16. Fluocinonide 17. Fluoxetine hydrochloride 18. Halcinonide 19. Ibuprofen; pseudoephedrine hydrochloride 20. Lidocaine 21. Morphine sulfate 22. Nicotine polacrilex 23. Nitisinone 24. Omega-3-acid ethyl esters type A 25. Oxycodone 26. Panobinostat lactate 27. Perampanel 28. Pimavanserin tartrate 29. Prazosin hydrochloride 30. Simvastatin 31. Tofacitinib citrate
And the revised draft product-specific BE recommendations include: Acyclovir; Albuterol sulfate; Buprenorphine hydrochloride, Naloxone hydrochloride (multiple reference listed drugs); Cobicistat, Darunavir ethanolate; Divalproex sodium (multiple reference listed drugs); Levomilnacipran hydrochloride; Medroxyprogesterone acetate; Nepafenac (multiple reference listed drugs); Omega-3-acid ethyl esters; Omega-3-carboxylic acids; Ruxolitinib phosphate; Tedizolid phosphate; and Venlafaxine hydrochloride.
The federal docket of previous BE product-specific recommendations can be viewed here and the specific guidance documents can be viewed at Product-Specific Recommendations for Generic Drug Development.
Tags: BE studies, generic drug guidance from FDA, active ingredients
Regulatory Focus newsletters
All the biggest regulatory news and happenings.